Published in J Clin Microbiol on August 01, 2005
New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol (2010) 1.25
PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep (2013) 1.17
Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol (2010) 1.16
Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis (2011) 1.02
Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high-risk individuals. J Clin Microbiol (2006) 0.95
Hepatitis C virus core antigen test in monitoring of dialysis patients. Hepat Res Treat (2012) 0.95
Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol (2015) 0.89
Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol (2014) 0.87
Quarantine Plasma: Quo vadis? Transfus Med Hemother (2010) 0.87
Current testing strategies for hepatitis C virus infection in blood donors and the way forward. World J Gastroenterol (2014) 0.87
Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test. J Virol Methods (2014) 0.84
Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay. Ann Gastroenterol (2013) 0.81
Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection. J Clin Microbiol (2006) 0.81
SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79
Diagnostic Performance of an Immunoassay for Simultaneous Detection of Hcv Core Antigen and Antibodies among Haemodialysis Patients. Braz J Microbiol (2011) 0.78
Diagnostic tests for hepatitis C: recent trends in electrochemical immunosensor and genosensor analysis. World J Gastroenterol (2014) 0.76
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. J Korean Med Sci (2016) 0.75
Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples. Transfusion (2015) 0.75
Evaluation of an antigen-antibody "combination" enzyme linked immunosorbent assay for diagnosis of hepatitis C virus infections. Ethiop J Health Sci (2014) 0.75
Comparison of monolisa HCV Ag/Ab ULTRA with two anti-HCV assays for the detection of HCV infection in hospital setting. Curr Microbiol (2011) 0.75
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med (2004) 5.78
Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion (2002) 2.53
Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion (2000) 2.42
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology (2002) 2.21
The UK blood transfusion service: over a (patent) barrel? Lancet (2002) 2.15
Use and interpretation of virological tests for hepatitis C. Hepatology (2002) 1.92
Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology (2000) 1.87
Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods (2004) 1.82
High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods (2003) 1.56
Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol (2004) 1.55
Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion (2002) 1.53
Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV antigen test in parallel with HCV RNA. Vox Sang (2004) 1.47
The first case of HCV infection detected before seroconversion in blood donors tested by HCV core antigen ELISA. Transfusion (2002) 1.44
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion (2003) 1.41
Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion (2002) 1.32
International application of the incidence rate/window period model. Transfusion (2002) 1.28
Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang (1995) 1.26
Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang (2004) 1.22
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion (2002) 1.16
Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection. Vox Sang (2000) 1.14
Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy. J Viral Hepat (2003) 1.12
Blood safety and nucleic acid testing in Europe. Euro Surveill (2005) 1.06
Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol (2002) 1.02
Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J Clin Microbiol (2004) 1.00
Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors. Transfus Med (2003) 0.98
Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion. N Engl J Med (1996) 0.98
A new HCV core antigen assay based on disassociation of immune complexes: an alternative to molecular biology in the diagnosis of early HCV infection. Transfusion (2003) 0.96
Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion (2002) 0.95
Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening. Transfusion (2003) 0.95
Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing. Vox Sang (2003) 0.93
HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion (2003) 0.92
Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users. J Clin Microbiol (2004) 0.91
Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill (2005) 0.87
HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet (2004) 0.86
HCV core antigen as an alternative to NAT to detect HCV viremia. Transfusion (2004) 0.85
Eradication of hepatitis C virus 1b by interferon in a health care worker with acute hepatitis following needlestick transmission from a patient with chronic hepatitis C unresponsive to interferon. Scand J Gastroenterol (2000) 0.84
Hepatitis C core antigen in Polish blood donors. Transfusion (2004) 0.83
Very low level viremia in HCV infectious unit missed by NAT. Transfusion (2003) 0.83
Evidence of hepatitis C virus viremia without detectable antibody to hepatitis C virus in a blood donor. Ann Intern Med (2000) 0.83
Nucleic acid testing in blood donations reactive to hepatitis C virus antibody, but with an extremely low viral load. Vox Sang (2004) 0.82
Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzer. Transfusion (2003) 0.81
[Interpretation of hepatitis C virus serology: immunoblot and genome amplification]. Transfus Clin Biol (2000) 0.78
HCV screening in blood donations using RT-PCR in mini-pool: the experience in Spain after routine use for 2 years. Transfusion (2003) 0.78
Acute HCV infection detected in a blood donor by NAT. Transfusion (2003) 0.77
[Application of molecular biology to blood transfusion safety: the nucleic acid testing]. Transfus Clin Biol (2003) 0.77
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med (2016) 6.22
Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis (2010) 3.00
Emergence of Toscana virus in Europe. Emerg Infect Dis (2005) 2.70
Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion (2002) 2.33
Genetic characterization of tick-borne flaviviruses: new insights into evolution, pathogenetic determinants and taxonomy. Virology (2006) 2.01
Transfusion-associated hepatitis E, France. Emerg Infect Dis (2007) 1.66
Ectoparasitism and vector-borne diseases in 930 homeless people from Marseilles. Medicine (Baltimore) (2005) 1.56
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) (2005) 1.51
Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol (2003) 1.49
A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases. Transfusion (2008) 1.42
Human parvovirus 4 in recipients of cellular products and in blood donors: epidemiologic similarity with B19 parvovirus. Transfusion (2009) 1.40
Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood (2005) 1.39
Changing epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis (2010) 1.36
Analysis of the 5' noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France. J Clin Microbiol (2006) 1.33
Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol (2002) 1.17
Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France. J Clin Microbiol (2005) 1.16
Hepatitis E virus infections in blood donors, France. Emerg Infect Dis (2014) 1.15
Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion. Transfusion (2004) 1.05
Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion (2005) 1.04
Marseillevirus prevalence in multitransfused patients suggests blood transmission. J Clin Virol (2013) 1.04
National survey of hepatitis B virus (HBV) polymorphism in asymptomatic HBV blood donors from 1999 to 2007 in France. Transfusion (2010) 1.04
Distribution and genetic analysis of TTV and TTMV major phylogenetic groups in French blood donors. J Med Virol (2006) 1.03
Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol (2006) 1.03
Parvovirus 4 in blood donors, France. Emerg Infect Dis (2010) 1.00
Human parvovirus 4 in kidney transplant patients, France. Emerg Infect Dis (2008) 1.00
Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion (2008) 0.98
Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol (2006) 0.98
Overestimation of incidence of hepatitis B virus mixed-genotype infections by use of the new line probe INNO-LiPA genotyping assay. J Clin Microbiol (2010) 0.98
Hepatitis E virus infection in sheltered homeless persons, France. Emerg Infect Dis (2010) 0.97
A new HCV core antigen assay based on disassociation of immune complexes: an alternative to molecular biology in the diagnosis of early HCV infection. Transfusion (2003) 0.96
Molecular characterization of genotype 2 and 4 hepatitis C virus isolates in French blood donors. J Med Virol (2008) 0.90
HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation. Transfusion (2003) 0.90
The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins. J Virol (2004) 0.89
Unique NS5b hepatitis C virus gene sequence consensus database is essential for standardization of genotype determinations in multicenter epidemiological studies. J Clin Microbiol (2006) 0.88
Evolution of hepatitis C virus in blood donors and their respective recipients. J Gen Virol (2003) 0.88
Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations. Transfusion (2006) 0.87
Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum. J Clin Microbiol (2004) 0.86
Circulating markers of oxidative stress and liver fibrosis in Sudanese subjects at risk of schistosomiasis and hepatitis. Acta Trop (2005) 0.85
Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits. J Clin Microbiol (2011) 0.84
Seroprevalence of Toscana virus in blood donors, France, 2007. Emerg Infect Dis (2011) 0.83
Analysis of hepatitis C virus strains circulating in Republic of the Congo. J Med Virol (2010) 0.83
Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping. J Clin Microbiol (2013) 0.82
Recombinant VP7-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Colorado tick fever virus. J Clin Microbiol (2003) 0.82
Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France. PLoS One (2012) 0.82
Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection. J Clin Microbiol (2010) 0.81
Hepatitis E. Vox Sang (2015) 0.79
Seroprevalence of West Nile virus in blood donors at Hôtel Dieu de France, Beirut, Lebanon. Transfusion (2010) 0.79
Feasibility study of a screening assay that identifies the abnormal prion protein PrPTSE in plasma: initial results with 20,000 samples. Transfusion (2010) 0.79
Recombinant VP9-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Banna virus (genus Seadornavirus). J Virol Methods (2004) 0.78
Multicenter trials need to use the same assay for hepatitis C virus viral load determination. J Clin Microbiol (2007) 0.77
Prevalence of IgG antibodies against West Nile virus in blood donors during the 2003 outbreak in Tunisia. Trans R Soc Trop Med Hyg (2010) 0.76
Multi-center evaluation of the hepatitis B surface antigen (HBsAg) assay and HbsAg confirmatory assay for the family of Access immunoassay systems. Clin Lab (2010) 0.76
Impact of hepatitis B virus genotypes and surface antigen variants on the performance of HBV real time PCR quantification. J Virol Methods (2009) 0.76
Evaluation of the enhanced bacterial detection system for screening of contaminated platelets. Transfusion (2006) 0.75
Convalescent Plasma for Ebola Virus Disease. N Engl J Med (2016) 0.75
Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. Emerg Infect Dis (2017) 0.75
Identification of apolipoprotein C-III as a potential plasmatic biomarker associated with the resolution of hepatitis C virus infection. Proteomics Clin Appl (2008) 0.75
Prevention of West Nile virus transmission by blood transfusion: a comparison of nucleic acid test screening assays. Transfusion (2005) 0.75
Staphylococcus aureus-contaminated apheresis platelets traced to donors' nasal carriage. Transfusion (2006) 0.75